Third, only two patients underwent germline genetic testing following the result of tumor sequencing because germline pathogenic BRCA1 and/or BRCA2 mutations are the only approved indication for targeted therapy in pancreatic cancer. Here, BRCA2 is linked to pancreatic neoplasm.